Table 1.
Baseline demographic and clinical characteristics
| Characteristics | SARS-CoV-2 positive <28 wk (n=402) | Not SARS-CoV-2 positive (n=11,705) | P value |
|---|---|---|---|
| Age (y) | 29.0±5.9 | 30.0±5.8 | .002 |
| BMI (kg/m2) | 29.3 (24.5–35.5) | 26.6 (23.0–31.9) | <.001 |
| BMI≥30 | 173 (46.0) | 3426 (32.2) | <.001 |
| BMI≥40 | 53 (14.1) | 799 (7.5) | <.001 |
| Race and ethnicity | <.001 | ||
| American Indian or Alaska Native | 0 (0) | 43 (0.4) | |
| Asian | 6 (1.6) | 575 (5.2) | |
| Hispanic | 188 (48.5) | 2614 (23.5) | |
| Native Hawaiian or Pacific Islander | 4 (1.0) | 28 (0.3) | |
| Non-Hispanic Black | 117 (30.2) | 2519 (22.6) | |
| Non-Hispanic White | 72 (18.6) | 5297 (47.6) | |
| More than 1 race | 1 (0.3) | 59 (0.5) | |
| No previous pregnancy ≥20 wk | 115 (28.7) | 4773 (40.8) | <.001 |
| Previous preterm birth (20 to <37 wk) | 51 (12.7) | 1077 (9.2) | .02 |
| Previous cesarean delivery | 90 (22.4) | 2149 (18.4) | .04 |
| Previous hypertensive disorders of pregnancy | 48 (12.0) | 922 (7.9) | .003 |
| Private insurance | 138 (34.7) | 6368 (54.8) | <.001 |
| Smoked during this pregnancy | 16 (4.0) | 846 (7.2) | .01 |
| Any substance use during this pregnancy | 25 (6.2) | 967 (8.3) | .14 |
| Immunocompromising condition | 5 (1.2) | 160 (1.4) | .83 |
| Asthma or COPD | 66 (16.4) | 1552 (13.3) | .07 |
| Pregestational diabetes mellitus | 20 (5.0) | 267 (2.3) | <.001 |
| Thrombophilia | 3 (0.7) | 79 (0.7) | .75 |
| Chronic hypertension | 37 (9.2) | 640 (5.5) | .001 |
| Chronic cardiovascular disease | 7 (1.7) | 175 (1.5) | .69 |
| Chronic renal disease | 4 (1.0) | 59 (0.5) | .16 |
| Chronic liver disease | 1 (0.2) | 107 (0.9) | .27 |
| Thyroid disease | 18 (4.5) | 791 (6.8) | .07 |
| Neurocognitive disorder | 32 (8.0) | 1551 (13.3) | .002 |
| Neuromuscular disorder | 1 (0.2) | 52 (0.4) | 1.00 |
| Seizure disorder | 4 (1.0) | 147 (1.3) | .64 |
| Inflammatory bowel disease | 2 (0.5) | 129 (1.1) | .33 |
| Any comorbidity (asthma or COPD, pregestational diabetes mellitus, chronic hypertension) | 104 (25.9) | 2217 (18.9) | <.001 |
| Trimester of SARS-CoV-2 positive | |||
| <14 wk | 44 (10.9) | ||
| 14 to <28 wk | 358 (89.1) |
Data are presented as mean±standard deviation, median (interquartile range), or number (percentage), unless otherwise specified. Non-Hispanic Asian, Native Hawaiian or Pacific Islander, American Indian or Alaskan Native, or more than 1 race were collapsed for statistical comparisons. The following are the number of missing values: maternal age (n=3), BMI (n=1083), race and ethnicity (n=584), parity (n=13), and insurance status (n=81).
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
Hughes. Early SARS-CoV-2 infection and subsequent pregnancy outcomes. Am J Obstet Gynecol 2023.